On December 8, 2020 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported that the Company will host a virtual event on Tuesday, December 15, 2020 at 11:00 AM ET to provide an update on the latest progress for its clinical pipeline (Press release, Precigen, DEC 8, 2020, View Source [SID1234572461]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will showcase data from several of the Company’s most advanced clinical programs, such as PRGN-3005 UltraCAR-T, PRGN-3006 UltraCAR-T and AG019 ActoBioticsTM. Precigen executives and key opinion leaders will participate in the event, including:

Helen Sabzevari, PhD, President and CEO of Precigen
Pieter Rottiers, PhD, CEO of Precigen ActoBio
Mary L. (Nora) Disis, MD, faculty member at the University of Washington and Fred Hutchinson Cancer Research Center and one of the lead investigators for the PRGN-3005 clinical study
Kevan Herold, MD, Professor of Immunobiology and of Medicine (Endocrinology) at Yale School of Medicine and one of the lead investigators for the AG019 clinical study
Participants may register and access the live webcast through Precigen’s investor relations website in the Press & Events section. An archived recording will be posted to the investor relations website following the event.